Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.87
DRTX's Cash to Debt is ranked higher than
59% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. DRTX: 0.87 )
DRTX' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: 0.87

Z-Score: 3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -182.82
DRTX's ROE (%) is ranked higher than
53% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. DRTX: -182.82 )
DRTX' s 10-Year ROE (%) Range
Min: -1188.24   Max: -150.73
Current: -182.82

-1188.24
-150.73
ROA (%) -67.12
DRTX's ROA (%) is ranked higher than
57% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. DRTX: -67.12 )
DRTX' s 10-Year ROA (%) Range
Min: -196.48   Max: -66.57
Current: -67.12

-196.48
-66.57
ROC (Joel Greenblatt) (%) -6864.28
DRTX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. DRTX: -6864.28 )
DRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12758.41   Max: -6067.31
Current: -6864.28

-12758.41
-6067.31
» DRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DRTX Guru Trades in

DRTX Guru Trades in

Q1 2014

DRTX Guru Trades in Q1 2014

Jim Simons 60,300 sh (New)
» More
Q2 2014

DRTX Guru Trades in Q2 2014

Jim Simons 66,200 sh (+9.78%)
» More
» Details

Insider Trades

Latest Guru Trades with DRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 139.90
DRTX's P/B is ranked higher than
56% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. DRTX: 139.90 )
DRTX' s 10-Year P/B Range
Min: 0   Max: 164.9
Current: 139.9

0
164.9
Current Ratio 3.76
DRTX's Current Ratio is ranked higher than
73% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. DRTX: 3.76 )
DRTX' s 10-Year Current Ratio Range
Min: 0.65   Max: 5.88
Current: 3.76

0.65
5.88
Quick Ratio 3.76
DRTX's Quick Ratio is ranked higher than
74% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. DRTX: 3.76 )
DRTX' s 10-Year Quick Ratio Range
Min: 0.65   Max: 5.88
Current: 3.76

0.65
5.88

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:DTA.Germany
Durata Therapeutics Inc is a clinical development stage biopharmaceutical company. The Company develops and commercializes novel therapeutics for patients with infectious diseases and acute illnesses.
» More Articles for DRTX

Headlines

Articles On GuruFocus.com
Three Stocks With Massive Insider Buying Sep 03 2014 
Ttreatment for skin Aug 05 2012 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Sep 19 2014
Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and... Sep 09 2014
Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on... Sep 03 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 28 2014
Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors Aug 26 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Aug 22 2014
DURATA THERAPEUTICS, INC. Financials Aug 15 2014
What Makes Durata Therapeutics (DRTX) a Strong Sell? Aug 13 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
Q2 2014 Durata Therapeutics Inc Earnings Release - Before Market Open Aug 07 2014
Durata Therapeutics Reports Second Quarter 2014 Financial Results Aug 07 2014
Durata Therapeutics to Present at Upcoming Investor Conference Aug 06 2014
Durata Therapeutics (DRTX) Worth Watching: Stock Gains 18.5% Aug 05 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 01 2014
The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata... Aug 01 2014
Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014 Jul 31 2014
Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to... Jul 30 2014
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Jul 30 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM) Jul 18 2014
Durata Therapeutics CEO buys 3,000 shares Jun 13 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK